Fig. 2: VCR-laden Lipo-SM-Chol increased the maximum tolerated dose (MTD) of VCR without systemic toxicities in healthy mice.
From: Cholesterol-modified sphingomyelin chimeric lipid bilayer for improved therapeutic delivery
a A table delineating the physicochemical characterizations of various VCR/Lipo with eq. 35 mol % Chol (40% Chol for Lipo-SM/Chol to match the ratio used in Marqibo) and 5% DSPE-PEG2K. DLC: drug loading capacity; DLE: drug loading efficiency. b Cryo-electron microscopy (cryo-EM) of Lipo-SM/Chol or Lipo-SM-CSS-Chol with or without VCR encapsulation. Scale bar: 100 nm, (n = 3 independent experiments, similar results were observed). c The mice weight monitoring in MTD study of free VCR, VCR/SML Lipo (Lipo-PChcPC), VCR/Lipo-SM/Chol, and VCR/Lipo-SM-CSS-Chol at various doses as indicated in healthy C57BL/J mice following a single i.v. administration via tail vein; Mice body weight and survival were monitored for 2 weeks. The MTD was defined by the dose that did not cause mouse death or more than 15% weight loss during the whole period36,84. d–g On day 14 post i.v. injection, blood was withdrawn for comprehensive thrombocytes (d), erythrocytes (e), leukocytes (f), and serum chemistry (g) analysis. Data in a (right portion, n = 3 independent experiments), c–g (n = 6 mice) are expressed as mean ± s.d. Statistical significance was determined by one-way ANOVA followed by Tukey’s multiple comparisons test. Source data are provided as a Source Data file.
